Dabi Amjad, Brown Joel S, Gatenby Robert A, Jones Corbin D, Schrider Daniel R
Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
Department of Cancer Biology and Evolution, Moffitt Cancer Center, Tampa, FL, USA.
bioRxiv. 2025 Jan 13:2024.11.26.625315. doi: 10.1101/2024.11.26.625315.
Cancers exhibit a remarkable ability to develop resistance to a range of treatments, often resulting in relapse following first-line therapies and significantly worse outcomes for subsequent treatments. While our understanding of the mechanisms and dynamics of the emergence of resistance during cancer therapy continues to advance, questions remain about how to minimize the probability that resistance will evolve, thereby improving long-term patient outcomes. Here, we present an evolutionary simulation model of a clonal population of cells that can acquire resistance mutations to one or more treatments. We leverage this model to examine the efficacy of a two-strike "extinction therapy" protocol, in which two treatments are applied sequentially to first contract the population to a vulnerable state and then push it to extinction, and compare it to a combination therapy protocol. We investigate how factors such as the timing of the switch between the two strikes, the rate of emergence of resistant mutations, the doses of the applied drugs, the presence of cross-resistance, and whether resistance is a binary or a quantitative trait affect the outcome. Our results show that the timing of switching to the second strike has a marked effect on the likelihood of driving the cancer to extinction, and that extinction therapy outperforms combination therapy when cross-resistance is present. We conduct an trial that reveals when and why a second strike will succeed or fail. Finally, we demonstrate that our conclusions hold whether we model resistance as a binary trait or as a quantitative, multi-locus trait.
癌症具有对一系列治疗产生耐药性的显著能力,这通常会导致一线治疗后复发,并使后续治疗的结果明显更差。虽然我们对癌症治疗期间耐药性出现的机制和动态的理解不断进步,但关于如何将耐药性演变的可能性降至最低,从而改善患者长期预后的问题仍然存在。在此,我们提出了一个细胞克隆群体的进化模拟模型,该模型中的细胞可以获得对一种或多种治疗的耐药性突变。我们利用这个模型来检验一种两次打击的“灭绝疗法”方案的疗效,在该方案中,两种治疗依次应用,首先将群体收缩到一个易受攻击的状态,然后将其推向灭绝,并将其与联合治疗方案进行比较。我们研究了两次打击之间的切换时间、耐药性突变的出现速率、所用药物的剂量、交叉耐药性的存在以及耐药性是二元性状还是数量性状等因素如何影响结果。我们的结果表明,切换到第二次打击的时间对将癌症推向灭绝的可能性有显著影响,并且当存在交叉耐药性时,灭绝疗法优于联合治疗。我们进行了一项试验,揭示了第二次打击何时以及为何会成功或失败。最后,我们证明,无论我们将耐药性建模为二元性状还是数量多基因座性状,我们的结论都成立。